Haleon Plc Form 6-K Summary
Business Context and Reporting Period
This Form 6-K filing by Haleon Plc covers the month of March 2026, with the report dated March 23, 2026. Haleon is a consumer health company focused on everyday health across six categories: Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health, and Therapeutic Skin Health. The filing specifically details transactions in the company's own shares under a share buyback programme announced on March 12, 2026.
Key Financial Metrics and Share Transactions
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on share repurchase activity. Between March 16 and March 20, 2026, Haleon purchased a total of 7,833,121 ordinary shares for cancellation. The transactions occurred across three trading venues: London Stock Exchange (LSE), CBOE (UK)/BXE, and CBOE (UK)/CXE Aquis.
| Date | Total Shares Purchased | Price Range (pence) | Weighted Avg Price (pence) |
|---|---|---|---|
| March 16, 2026 | 999,097 | 377.10 - 387.00 | ~384.90 |
| March 17, 2026 | 1,040,235 | 387.40 - 393.90 | ~390.60 |
| March 18, 2026 | 1,793,789 | 385.10 - 394.30 | ~388.20 |
| March 19, 2026 | 2,500,000 | 378.20 - 385.60 | ~381.00 |
| March 20, 2026 | 1,500,000 | 375.90 - 382.20 | ~378.40 |
Following these transactions, the company's registered share capital stands at 8,941,771,041 ordinary shares of £0.01 each. Of these, 12,591,821 are held as treasury shares, leaving 8,929,179,220 ordinary shares with voting rights.
Material Changes and Outlook
The filing does not report material changes to financial performance, guidance, or outlook compared to prior periods. It does not contain management commentary on operational risks, contingencies, or unusual items beyond the execution of the share buyback programme. The primary change reported is the reduction in the number of shares outstanding due to the cancellation of the purchased shares.
Investor Verification Checklist
- Verify the total number of shares purchased (7,833,121) and the specific dates of execution (March 16-20, 2026).
- Confirm the updated number of voting shares (8,929,179,220) for disclosure threshold calculations under FCA rules.
- Review the full breakdown of individual trades available via the provided RNS link for granular pricing data.
- Note that this filing contains no financial performance data (revenue, earnings, cash flow) for the period.